Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 11—November 2023
Research

Systematic Review and Meta-analysis of Deaths Attributable to Antimicrobial Resistance, Latin America

Agustín CiapponiComments to Author , Ariel Bardach, María Macarena Sandoval, María Carolina Palermo, Emiliano Navarro, Carlos Espinal, and Rodolfo Quirós
Author affiliations: Centro de Investigaciones Epidemiológicas y Salud Pública (CIESP), Buenos Aires, Argentina (A. Ciapponi, A. Bardach); Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires (A. Ciapponi, A. Bardach, M.M. Sandoval, M.C. Palermo, E. Navarro); Florida International University, Miami, Florida, USA (C. Espinal, R. Quirós); Sanatorio Las Lomas, Buenos Aires (R. Quirós)

Main Article

Figure 3

Adjusted odds ratios between antimicrobial resistance and lethality by appropriate empirical antibiotic treatment (considering the definition of appropriate empirical treatment given by each author) in systematic review and meta-analysis of deaths attributable to antimicrobial resistance, Latin America. Death-R indicates death in the resistant group; Death-S indicates death in the susceptible group. Error bars indicate 95% CIs. CR-AB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacterales; CR-PA, carbapenem-resistant Pseudomonas aeruginosa; ESBL-E, extended-spectrum β-lactamase–producing Enterobacterales; MDR-GNB, multidrug-resistant gram-negative bacilli (including ESBL-E, CRE, CR-PA, CR-AB); MDRO, multidrug-resistant organisms (including MRSA, vancomycin-resistant Enterococcus, ESLB-E, CRE, CR-PA, CR-AB); MRSA, methicillin-resistant Staphylococcus aureus; NR, not reported; OR, odds ratio.

Figure 3. Adjusted odds ratios between antimicrobial resistance and lethality by appropriate empirical antibiotic treatment (considering the definition of appropriate empirical treatment given by each author) in systematic review and meta-analysis of deaths attributable to antimicrobial resistance, Latin America. Death-R indicates death in the resistant group; Death-S indicates death in the susceptible group. Error bars indicate 95% CIs. CR-AB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacterales; CR-PA, carbapenem-resistant Pseudomonas aeruginosa; ESBL-E, extended-spectrum β-lactamase–producing Enterobacterales; MDR-GNB, multidrug-resistant gram-negative bacilli (including ESBL-E, CRE, CR-PA, CR-AB); MDRO, multidrug-resistant organisms (including MRSA, vancomycin-resistant Enterococcus, ESLB-E, CRE, CR-PA, CR-AB); MRSA, methicillin-resistant Staphylococcus aureus; NR, not reported; OR, odds ratio.

Main Article

Page created: September 20, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external